• Je něco špatně v tomto záznamu ?

Prognostic value of tumor-infiltrating lymphocytes (TILs) and their association with PD-L1 expression and DNA repair protein RAD51 in patients with resected non-small cell lung carcinoma

M. Gachechiladze, J. Škarda, D. Skanderová, I. Überall, V. Kolek, P. Smičkova, P. Vojta, J. Vbrková, M. Hajdúch, I. Shani, Z. Kolář, R. Stahel, W. Weder, U. Rulle, A. Soltermann, M. Joerger

. 2020 ; 147 (-) : 30-38. [pub] 20200623

Jazyk angličtina Země Irsko

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc21020205

OBJECTIVES: DNA repair proteins have emerged as potential predictors for immunotherapy response alongside PD-L1 expression, tumor-infiltrating lymphocytes (TILs) and tumor mutational burden. We analyzed expression of PD-L1, TILs count and expression of the homologous recombination (HR) protein RAD51, as potential prognostic factors in patients with resected non-small-cell lung carcinoma (NSCLC). MATERIALS AND METHODS: Discovery set included 96 NSCLC patients from the University Hospital Olomouc (Czech Republic) and a replication set included 1109 NSCLC patients from University Hospital Zurich (Switzerland). Tissue microarrays (TMAs) were stained using the automated staining platform Ventana Benchmark Ultra with antibodies against RAD51,CD3, CD8, CD68 and PD-L1. RESULTS: Loss of nuclear RAD51 protein was associated with high TILs (r=-0.25, p = 0.01) and PD-L1 status (10.6 vs. 2.4 %, p = 0.012) in patients receiving neoadjuvant chemo-/radiotherapy (CT/RT). In silico analysis from the TCGA data set showed a negative relationship between RAD51 mRNA expression and CD45 (r = ‒0.422, p < 0.0001), CD68 (r = ‒0.326, p < 0.001), CD3 (r = ‒0.266, p < 0.001) and CD8 (r = ‒0.102, p < 0.001). RAD51 low/PD-L1 high patients were clustered as separate entity in the replication set and in TCGA dataset. High TILs status was significantly associated with improved OS in the replication set (unadjusted HR = 0.57, 95 % CI 0.42-0.76, p < 0.001). Similar results have been seen for CD3, CD8 and CD68. CONCLUSIONS: In conclusion, RAD51 nuclear loss is weakly associated with increased TILs and high PD-L1 at the time of surgery in curatively resected NSCLC and after prior exposure to neoadjuvant chemo- or radiotherapy. Both high TILs and RAD51 nuclear loss were confirmed as independent prognostic factors in curatively resected NSCLC.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21020205
003      
CZ-PrNML
005      
20230109124915.0
007      
ta
008      
210728s2020 ie f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.lungcan.2020.06.025 $2 doi
035    __
$a (PubMed)32653671
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a ie
100    1_
$a Gachechiladze, Mariam $u Department of Clinical and Molecular Pathology, Institute of Translational and Molecular Medicine, Faculty of Medicine and Dentistry, Palacky University, Hnevotinska 3, 775 15, Olomouc, Czech Republic. Electronic address: mariam.gachechiladze@upol.cz
245    10
$a Prognostic value of tumor-infiltrating lymphocytes (TILs) and their association with PD-L1 expression and DNA repair protein RAD51 in patients with resected non-small cell lung carcinoma / $c M. Gachechiladze, J. Škarda, D. Skanderová, I. Überall, V. Kolek, P. Smičkova, P. Vojta, J. Vbrková, M. Hajdúch, I. Shani, Z. Kolář, R. Stahel, W. Weder, U. Rulle, A. Soltermann, M. Joerger
520    9_
$a OBJECTIVES: DNA repair proteins have emerged as potential predictors for immunotherapy response alongside PD-L1 expression, tumor-infiltrating lymphocytes (TILs) and tumor mutational burden. We analyzed expression of PD-L1, TILs count and expression of the homologous recombination (HR) protein RAD51, as potential prognostic factors in patients with resected non-small-cell lung carcinoma (NSCLC). MATERIALS AND METHODS: Discovery set included 96 NSCLC patients from the University Hospital Olomouc (Czech Republic) and a replication set included 1109 NSCLC patients from University Hospital Zurich (Switzerland). Tissue microarrays (TMAs) were stained using the automated staining platform Ventana Benchmark Ultra with antibodies against RAD51,CD3, CD8, CD68 and PD-L1. RESULTS: Loss of nuclear RAD51 protein was associated with high TILs (r=-0.25, p = 0.01) and PD-L1 status (10.6 vs. 2.4 %, p = 0.012) in patients receiving neoadjuvant chemo-/radiotherapy (CT/RT). In silico analysis from the TCGA data set showed a negative relationship between RAD51 mRNA expression and CD45 (r = ‒0.422, p < 0.0001), CD68 (r = ‒0.326, p < 0.001), CD3 (r = ‒0.266, p < 0.001) and CD8 (r = ‒0.102, p < 0.001). RAD51 low/PD-L1 high patients were clustered as separate entity in the replication set and in TCGA dataset. High TILs status was significantly associated with improved OS in the replication set (unadjusted HR = 0.57, 95 % CI 0.42-0.76, p < 0.001). Similar results have been seen for CD3, CD8 and CD68. CONCLUSIONS: In conclusion, RAD51 nuclear loss is weakly associated with increased TILs and high PD-L1 at the time of surgery in curatively resected NSCLC and after prior exposure to neoadjuvant chemo- or radiotherapy. Both high TILs and RAD51 nuclear loss were confirmed as independent prognostic factors in curatively resected NSCLC.
650    _2
$a antigeny CD274 $x genetika $7 D060890
650    12
$a nemalobuněčný karcinom plic $x genetika $x terapie $7 D002289
650    _2
$a oprava DNA $7 D004260
650    _2
$a lidé $7 D006801
650    12
$a nádory plic $x genetika $x terapie $7 D008175
650    _2
$a tumor infiltrující lymfocyty $7 D016246
650    _2
$a prognóza $7 D011379
650    _2
$a rekombinasa Rad51 $x genetika $7 D051135
651    _2
$a Švýcarsko $7 D013557
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Škarda, Josef $u Department of Clinical and Molecular Pathology, Institute of Translational and Molecular Medicine, Faculty of Medicine and Dentistry, Palacky University, Hnevotinska 3, 775 15, Olomouc, Czech Republic
700    1_
$a Skanderová, Daniela $u Department of Clinical and Molecular Pathology, Institute of Translational and Molecular Medicine, Faculty of Medicine and Dentistry, Palacky University, Hnevotinska 3, 775 15, Olomouc, Czech Republic
700    1_
$a Überall, Ivo $u Department of Clinical and Molecular Pathology, Institute of Translational and Molecular Medicine, Faculty of Medicine and Dentistry, Palacky University, Hnevotinska 3, 775 15, Olomouc, Czech Republic
700    1_
$a Kolek, Vítězslav $u Department of Tuberculosis and Respiratory Diseases, Faculty of Medicine and Dentistry, Palacky University and University Hospital, Olomouc, Czech Republic
700    1_
$a Smičkova, Petra $u Department of Tuberculosis and Respiratory Diseases, Faculty of Medicine and Dentistry, Palacky University and University Hospital, Olomouc, Czech Republic
700    1_
$a Vojta, Petr $u Laboratory of Genomics, Institute of Molecular and Translational Medicine Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic
700    1_
$a Vbrková, Jana $u Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University and University Hospital in Olomouc, Olomouc, Czech Republic
700    1_
$a Hajdúch, Marián $u Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University and University Hospital in Olomouc, Olomouc, Czech Republic
700    1_
$a Shani, Ilay $u Faculty of Medicine and Dentistry, Palacky University Olomouc, Czech Republic
700    1_
$a Kolář, Zdeněk $u Department of Clinical and Molecular Pathology, Institute of Translational and Molecular Medicine, Faculty of Medicine and Dentistry, Palacky University, Hnevotinska 3, 775 15, Olomouc, Czech Republic
700    1_
$a Stahel, Rolf A., $u Clinic of Oncology, University Hospital, Zurich, Switzerland $d 1950- $7 xx0280332
700    1_
$a Weder, Walter $u Department of Thoracic Surgery, University Hospital, Zurich, Switzerland
700    1_
$a Rulle, Undine $u Department of Pathology and Molecular Pathology, University Hospital, Zurich, Switzerland
700    1_
$a Soltermann, Alex $u Department of Pathology and Molecular Pathology, University Hospital, Zurich, Switzerland
700    1_
$a Joerger, Markus $u Department of Medical Oncology and Hematology, Cantonal Hospital, CH-9007, St. Gallen, Switzerland
773    0_
$w MED00003160 $t Lung cancer $x 1872-8332 $g Roč. 147, č. - (2020), s. 30-38
856    41
$u https://pubmed.ncbi.nlm.nih.gov/32653671 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20210728 $b ABA008
991    __
$a 20230109124912 $b ABA008
999    __
$a ok $b bmc $g 1690907 $s 1140651
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 147 $c - $d 30-38 $e 20200623 $i 1872-8332 $m Lung cancer $n Lung Cancer $x MED00003160
LZP    __
$a Pubmed-20210728

Najít záznam

Citační ukazatele

Možnosti archivace